Collegium Pharmaceutical Inc (NAS:COLL)

$ 31.68 0.1 (0.32%) Market Cap: 1.04 Bil Enterprise Value: 1.35 Bil PE Ratio: 13.15 PB Ratio: 4.66 GF Score: 73/100

Q4 2023 Collegium Pharmaceutical Inc Earnings Call Transcript
Feb 22, 2024

$32.81 (+3.31%)

Earnings
Q3 2023 Collegium Pharmaceutical Inc Earnings Call Transcript
Nov 07, 2023

$21.68 (-1.90%)

Earnings
Q2 2023 Collegium Pharmaceutical Inc Earnings Call Transcript
Aug 03, 2023

$22.02 (+0.09%)

Earnings
Collegium Pharmaceutical Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Q1 2023 Collegium Pharmaceutical Inc Earnings Call Transcript
May 04, 2023

$22.2 (+0.41%)

Earnings
Collegium Pharmaceutical Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 18, 2023
Q4 2022 Collegium Pharmaceutical Inc Earnings Call Transcript
Feb 23, 2023

$26.6 (+0.72%)

Earnings
Q3 2022 Collegium Pharmaceutical Inc Earnings Call Transcript
Nov 03, 2022

$18.03 (+2.27%)

Earnings
Q2 2022 Collegium Pharmaceutical Inc Earnings Call Transcript
Aug 04, 2022

$18.51 (+2.55%)

Earnings
Q1 2022 Collegium Pharmaceutical Inc Earnings Call Transcript
May 10, 2022

$14.48 (+1.83%)

Earnings
Q4 2021 Collegium Pharmaceutical Inc Earnings Call Transcript
Feb 24, 2022

$21.4 (-4.89%)

Earnings
Collegium Pharmaceutical Inc To Acquire BioDelivery Sciences International Inc - M&A Call Transcript
Feb 14, 2022
Q3 2021 Collegium Pharmaceutical Inc Earnings Call Transcript
Nov 04, 2021

$19.35 (-3.83%)

Earnings
Q2 2021 Collegium Pharmaceutical Inc Earnings Call Transcript
Aug 05, 2021

$24.84 (-0.40%)

Earnings
Q1 2021 Collegium Pharmaceutical Inc Earnings Call Transcript
May 06, 2021

$21.94 (-1.17%)

Earnings
Q4 2020 Collegium Pharmaceutical Inc Earnings Call Transcript
Feb 25, 2021

$26.03 (-0.27%)

Earnings
Q3 2020 Collegium Pharmaceutical Inc Earnings Call Transcript
Nov 05, 2020

$20.03 (+4.21%)

Earnings
Q2 2020 Collegium Pharmaceutical Inc Earnings Call Transcript
Aug 05, 2020

$17.31 (+3.90%)

Earnings
Q1 2020 Collegium Pharmaceutical Inc Earnings Call Transcript
May 07, 2020

$20.33 (+3.57%)

Earnings
Collegium Pharmaceutical Inc at Needham Healthcare Conference Transcript
Apr 14, 2020
Q4 2019 Collegium Pharmaceutical Inc Earnings Call Transcript
Feb 27, 2020

$21.68 (-3.94%)

Earnings
Q3 2019 Collegium Pharmaceutical Inc Earnings Call Transcript
Nov 06, 2019

$13.7 (-0.15%)

Earnings
Q2 2019 Collegium Pharmaceutical Inc Earnings Call Transcript
Aug 07, 2019

$10.61 (-0.93%)

Earnings
Q1 2019 Collegium Pharmaceutical Inc Earnings Call Transcript
May 08, 2019

$14.05 (+0.50%)

Earnings
Q4 2018 Collegium Pharmaceutical Inc Earnings Call Transcript
Feb 27, 2019

$14.45 (-2.63%)

Earnings

Collegium Pharmaceutical Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 18, 2023 / 06:15PM GMT

Release Date Price: $23.14 (-0.13%)

Transcript

Serge Belanger

Needham & Company, LLC - Analyst

Hi, good afternoon. I'm Serge Belanger. I'm one of the senior healthcare analysts at Needham. I want to welcome you to Needham's 22nd Annual Healthcare Conference. And for our next session, we have the Collegium Pharmaceuticals team. We have the CEO and President, Joe Ciaffoni; as well as the CFO, Colleen Tupper.

So I'll hand it over to Joe to get us started. He'll give us a quick overview of the company and then we'll go to questions. (Conference Instructions) So Joe, please.

Joe Ciaffoni

Collegium Pharmaceutical, Inc. - President & CEO

Great. And Serge, thank you as always, for the opportunity to participate in the conference. Colleen and I appreciate that opportunity very much. 2023 for Collegium is a year we're excited about. We believe 2023 will be a banner year, and that's what we're setting out to achieve. We're proud of our leading commercial portfolio.

We have a strong financial position, and we're committed to taking a disciplined approach to capital deployment with the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.